A Cell Press partner journal
See the unseen. Change the unchanged.
The Innovation ¡ª published by Cell Press in partnership with members of the Youth
Innovation Promotion Association (YIPA),a part of the Chinese Academy of
Sciences¡ªis a new broad-scope, open access journal publishing basic and applied
research that has impact for the benefit of society.
On the cover: Medicine is the practice of the diagnosis, treatment, and prevention of disease. With the advances in medical science, human beings are getting both longer life spans and higher quality of life. From herbs to molecular signatures, humankind is experiencing a transition from traditional medicine to personalized medicine: the right treatment to the right patient at the right time. However, it is not so easy to achieve this goal because the etiology of most diseases and disorders is still unclear. From description to association, numerous researchers are working together to decipher the mechanisms behind disease. To address such challenges, more and more global collaborations are badly needed to include experts from all disciplines: not just doctors, scientists and administration staff, but also engineers, technicians and marketing managers. Not limited to a fish-eye view, we humans should widen our vision and get more deep insights beyond the human community. That is the right way to assure sustainable healthcare for humanity.
  Related comments
Add comment (English only)
Name*:  
E-mail:  
Telephone:  
Code:    
Comments*:
Position: Home > issue > May 10, 2022 Volume 3, Issue 3
Toripalimab in advanced biliary tract cancer
Category:   Report   Download:  PDF  Figure  Endnote
Author: Wei Li, Yueqi Wang, Yiyi Yu, Qian Li, Yan Wang, Chenlu Zhang, Xiaojing Xu, Xi Guo, Yu Dong, Yuehong Cui, Qing Hao, Lujia Huang, Houbao Liu, Tianshu Liu

e2.jpg

GRAPHICAL ABSTRACT


Gemcitabine combined with platinum/fluorouracil drugs is the standard first-line treatment for advanced biliary tract cancers (BTCs). This study explored the safety and efficacy of Toripalimab plus gemcitabine and S-1 (GS) as the first-line treatment for advanced BTCs. At a one-sided significance level of 0.025, a total of 50 patients could provide 80% power to show the efficacy at targeted progression free survival rate at 6 months of 70% versus 40% for the combined treatment. This single-arm, phase II study enrolled 50 patients with advanced BTCs who previously received no systemic treatment.





Host
ISSN 2666-6758
Publishing partner
Journal links
 
Academic co-partner
SHANGHAI INSTITUTE OF APPLIED PHYSICS, CAS
INSTITUTE OF MICROBIOLOGY, CAS
XI'AN INSTITUTE OF OPTICS AND PRECISION MECHANICS, CAS
 
Collections

Air Pollution
Astronomy
Cancer
Chemistry & Materials
COVID-19
Environment Changes
Geoscience
Life Science & Medicine
Physics
ScienceX / Interdiscipline

 
Stay connected
  the.innovation.journal
  the.innovation.journal
  The Innovation
  TheInnovation´´ÐÂ
  TheInnovation´´ÐÂ
  The_Innovation
  office@the-innovation.org
  Official£º
Astronomy£º
Chemistry£º
Geoscience£º
Informatics£º
Life Science£º
Management£º
Materials£º
Medicine£º
Physics£º
ScienceX£º

@The_InnovationJ
@Innov_Astronomy
@InnovationChem
@Innov_Geosci
@Innov_inf
@Innov_LifeSci
@Innov_MGT
@Innov_Materials
@Innov_Medicine
@InnovationPhys
@Innov_ScienceX

  Copyright © 2019-2022 the-innovation.org All Rights Reserved